Skip to main content

Peer Review reports

From: Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

Original Submission
12 Oct 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
6 Jan 2022 Reviewed Reviewer Report - Michael S. Broder
8 Jan 2022 Reviewed Reviewer Report
3 Feb 2022 Reviewed Reviewer Report - Lara Kujtan
15 Feb 2022 Author responded Author comments - Chan Shen
Resubmission - Version 4
15 Feb 2022 Submitted Manuscript version 4
21 Feb 2022 Author responded Author comments - Chan Shen
Resubmission - Version 5
21 Feb 2022 Submitted Manuscript version 5
10 Mar 2022 Reviewed Reviewer Report
14 Mar 2022 Author responded Author comments - Chan Shen
Resubmission - Version 6
14 Mar 2022 Submitted Manuscript version 6
Publishing
21 Mar 2022 Editorially accepted
9 Apr 2022 Article published 10.1186/s12913-022-07857-y

You can find further information about peer review here.

Back to article page